<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00937066</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-RC0-SYM-2007/1</org_study_id>
    <nct_id>NCT00937066</nct_id>
  </id_info>
  <brief_title>Cost-effectiveness Study of Symbicort as Maintenance and Reliever Therapy (SMART)</brief_title>
  <official_title>Management of Patients With Moderate to Severe Asthma Uncontrolled When Treated With Low Dose Inhaled Corticosteroids: Cost-effectiveness of Three Therapeutics Alternatives</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an economic evaluation of Symbicort (Budesonide/formoterol) as maintenance and&#xD;
      reliever therapy (SMART) versus its competitive alternatives.&#xD;
&#xD;
      The aims of this study are:&#xD;
&#xD;
        -  To estimate the relative effectiveness of each one of the alternatives in the management&#xD;
           of patients with moderate to severe asthma through a systematic review for the following&#xD;
           outcomes:&#xD;
&#xD;
             -  Cumulative incidence of asthma severe exacerbations symptoms&#xD;
&#xD;
             -  Safety of each alternative (frequency of adverse events and complications due to&#xD;
                the medications)&#xD;
&#xD;
        -  To estimate the direct medical costs of treating with each pharmacologic alternative:&#xD;
           Symbicort as SMART versus increased use of inhaled corticosteroids or Adding long-acting&#xD;
           inhaled beta 2 agonist plus inhaled corticosteroids.&#xD;
&#xD;
        -  To create a decision analysis model (decision tree) that allows comparisons between the&#xD;
           alternatives on expected values and costs.&#xD;
&#xD;
        -  To calculate the average and incremental cost-effectiveness ratios.&#xD;
&#xD;
        -  To carry out a sensitivity analysis to test de robustness of the cost-effectiveness&#xD;
           results allowing for reasonable changes in expected values and costs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate incremental cost-effectiveness ratio using Symbicort as Maintenance and Reliever Therapy in the pharmacologic management of patients when compared with competitive alternatives</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incremental cost-effectiveness ratio from using Symbicort as symbicort as Maintenance and Reliever Therapy when compared with its competitive alternatives</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1000</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Adult patients 18-65 years with moderate to severe uncontrolled asthma</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Moderate to severe asthma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodolfo Dennis, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Pontificia Universidad Javeriana</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MAR√çA XIMENA ROJAS, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pontificia Universidad Javeriana</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>July 9, 2009</study_first_submitted>
  <study_first_submitted_qc>July 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2009</study_first_posted>
  <last_update_submitted>January 21, 2011</last_update_submitted>
  <last_update_submitted_qc>January 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>MC MD</name_title>
    <organization>AstraZeneca Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Cost-effectiveness analysis</keyword>
  <keyword>Symbicort</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

